top of page


Scleral Cross-linking Using Riboflavin and Ultraviolet-A Radiation for Prevention of Axial Myopia in a Rabbit Model.

Dotan A, Kremer I, Gal-Or O, Livnat T, Zigler A, Bourla D, Weinberger D.

J Vis Exp. 2016 Apr 3;(110):

Bevacizumab clearance through the iridocorneal angle following intravitreal injection in a rat model.

Gal-Or O, Dotan A, Dachbash M, Tal K, Nisgav Y, Weinberger D, Ehrlich R, Livnat T.

Exp Eye Res. 2016 Apr;145:412-6. doi: 10.1016/j.exer.2016.02.006. Epub 2016 Feb 26.

Scleral cross-linking using riboflavin and ultraviolet-a radiation for prevention of progressive myopia in a rabbit model.

Dotan A, Kremer I, Livnat T, Zigler A, Weinberger D, Bourla D.

Exp Eye Res. 2014 Oct;127:190-5. doi: 10.1016/j.exer.2014.07.019. Epub 2014 Aug 8.

Intracameral recombinant tissue plasminogen activator (r-tPA) for refractory toxic anterior segment syndrome.

Dotan A, Kaiserman I, Kremer I, Ehrlich R, Bahar I.

Br J Ophthalmol. 2014 Feb;98(2):252-5. doi: 10.1136/bjophthalmol-2013-304294. Epub 2013 Nov 25.

Contralateral lateral rectus muscle recession in patients with Duane retraction syndrome type 3.

Snir M, Dotan A, Friling R, Ron-Kella Y, Goldenberg-Cohen N, Stiebel-Kalish H.

Eye (Lond). 2014 Mar;28(3):279-84. doi: 10.1038/eye.2013.260. Epub 2013 Dec 6.

Intravitreous bevacizumab treatment for macular edema due to central retinal vein occlusion.

Axer-Siegel R, Dotan A, Mimouni K, Bor E, Weinberger D, Bourla DH.

Curr Eye Res. 2012 Sep;37(9):818-22. doi: 10.3109/02713683.2012.678543. Epub 2012 Jun 5.

Consecutive appearance of corneal subepithelial infiltrates after intravitreous bevacizumab injections.

Bourla DH, Dotan A, Weinberger D, Bourla N, Kremer I.

Cornea. 2010 Jun;29(6):686-7. doi: 10.1097/ICO.0b013e3181ba0cc7.

bottom of page